Corporate Profile

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. We are developing a novel and proprietary class of product candidates, led by KORSUVA (difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system and on immune cells.

Contact IR
email alerts